KalVista Pharmaceuticals, Inc.
KALVDelisted Jun 11, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001348911
KalVista Pharmaceuticals, Inc. was delisted on Jun 11, 2026; its insiders filed their last Form 4 on Jun 11, 2026; 184 institutions reported holding it in 13F filings for Q1 2026, worth $1.39B in total; no superinvestor held it.
Q3 2024 vs. Q2 2024
How the institutions holding KalVista Pharmaceuticals, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 119 | 2 | 122 | +5 |
| Shares | 48.2M | 3.01M | 48.4M | +3.19M (+7.1%) |
| Value | $568.2M | $35.5M | $561.0M | +$28.2M (+5.3%) |
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held KalVista Pharmaceuticals, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 3,062,319 | $35.5M | 0.00% |
| Readystate Asset Management LP | 180,000 | $2.08M | 0.11% |
| Rafferty Asset Management, LLC | 43,830 | $507.6K | 0.00% |
| Balyasny Asset Management LLC | 26,968 | $312.3K | 0.00% |
| Squarepoint Ops LLC | 25,749 | $298.2K | 0.00% |
| PDT Partners, LLC | 22,454 | $260.0K | 0.02% |
| Paloma Partners Management Co | 17,924 | $207.6K | 0.01% |
| Quest Partners LLC | 15,112 | $175.0K | 0.02% |
| SG Americas Securities, LLC | 13,189 | $153.0K | 0.00% |
| AQR Capital Management LLC | 12,354 | $143.1K | 0.00% |
| Intech Investment Management LLC | 10,855 | $125.7K | 0.00% |
| Group One Trading, L.P. | 3,500 | $40.5K | 0.00% |
| Venturi Wealth Management, LLC | 410 | $4.75K | 0.00% |
| Bessemer Group Inc | 45 | $1.00K | 0.00% |
| Parallel Advisors, LLC | 68 | $787 | 0.00% |
| GAMMA Investing LLC | 59 | $683 | 0.00% |
| Sterling Capital Management LLC | 39 | $452 | 0.00% |
| National Bank of Canada | 1 | $12 | 0.00% |
Sold out (13)
Institutions that held KalVista Pharmaceuticals, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| StemPoint Capital LP | 736,765 | $8.68M |
| Driehaus Capital Management LLC | 535,717 | $6.31M |
| Perceptive Advisors LLC | 500,000 | $5.89M |
| Nicholas Investment Partners, LP | 184,358 | $2.17M |
| Norges Bank | 131,300 | $1.55M |
| Corton Capital Inc. | 39,593 | $466.4K |
| Campbell & CO Investment Adviser LLC | 25,522 | $300.6K |
| Legato Capital Management LLC | 23,674 | $278.9K |
| Atom Investors LP | 19,901 | $234.4K |
| Verition Fund Management LLC | 15,113 | $178.0K |
| AlphaCentric Advisors LLC | 2,500 | $29.4K |
| Innealta Capital, LLC | 30 | $353 |
| Farther Finance Advisors, LLC | 13 | $155 |
Not filed for Q3 2024 yet (2)
Institutions that held KalVista Pharmaceuticals, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 2,945,116 | $34.7M |
| Susquehanna Fundamental Investments, LLC | 68,526 | $807.2K |